Download PDF
Semin Respir Crit Care Med 2018; 39(03): 297-309
DOI: 10.1055/s-0038-1660863
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Updates in the Treatment of Active and Latent Tuberculosis

Michelle K. Haas
1   Denver Metro Tuberculosis Program, Denver Public Health, Denver, Colorado
2   Division of Infectious Diseases, Department of Medicine, University of Colorado-Denver Anschutz Medical Campus, Aurora, Colorado
,
Robert W. Belknap
1   Denver Metro Tuberculosis Program, Denver Public Health, Denver, Colorado
2   Division of Infectious Diseases, Department of Medicine, University of Colorado-Denver Anschutz Medical Campus, Aurora, Colorado
› Author Affiliations
Further Information

Publication History

Publication Date:
02 August 2018 (online)

    Permissions and Reprints

Abstract

First-line therapy for active tuberculosis (TB) has remained unchanged for nearly 40 years. Isoniazid, rifampin, pyrazinamide, and ethambutol for the initial two-month phase followed by isoniazid and rifampin for 4 to 7 months is standard treatment for people at low risk for drug-resistant disease. Directly-observed therapy (DOT) remains the standard of care for pulmonary TB. Virtual treatment monitoring using digital technologies is becoming more common as a way to provide a more patient-centered approach to care. Attempts to shorten treatment duration have been unsuccessful based on recent clinical trials evaluating the role of fluoroquinolones. Treatment-shortening trials using higher doses of rifamycins are currently underway. Recently approved medications for TB treatment are recommended only for drug-resistant disease, but novel agents in varying stages of development are being evaluated. Rifamycin-based regimens for latent TB infection (LTBI) have been successful in preventing progression to TB disease. Once-weekly isoniazid and rifapentine for 12 weeks by DOT was shown to be safe and effective compared with 9 months of isoniazid. The same regimen was shown to have acceptable treatment completion when given self-administered. Newer studies are investigating even shorter LTBI treatment with durations of less than 2 months. Treatment of LTBI in people likely infected with multidrug resistant TB is very limited, but one observational study found that fluoroquinolones appear to be effective. The first randomized trials for treating LTBI in contacts to MDR-TB are currently enrolling.

Keywords

active tuberculosis - latent tuberculosis - treatment - isoniazid - rifampin - rifapentine - directly observed therapy
 

  • References

  • 1 Global Tuberculosis Report 2017. Geneva, Switzerland: World Health Organization; 2017
    Google Scholar
  • 2 Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52 (06) 793-800
    CrossrefPubMedGoogle Scholar
  • 3 Naidoo P, Theron G, Rangaka MX. , et al. The South African Tuberculosis Care Cascade: estimated losses and methodological challenges. J Infect Dis 2017; 216 (Suppl. 07) S702-S713
    CrossrefPubMedGoogle Scholar
  • 4 Cazabon D, Alsdurf H, Satyanarayana S. , et al. Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. Int J Infect Dis 2017; 56: 111-116
    CrossrefPubMedGoogle Scholar
  • 5 Subbaraman R, Nathavitharana RR, Satyanarayana S. , et al. The tuberculosis cascade of care in India's public sector: a systematic review and meta-analysis. PLoS Med 2016; 13 (10) e1002149
    CrossrefPubMedGoogle Scholar
  • 6 Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119 (04) 579-585
    PubMedGoogle Scholar
  • 7 Johnson JL, Hadad DJ, Dietze R. , et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009; 180 (06) 558-563
    CrossrefPubMedGoogle Scholar
  • 8 Benator D, Bhattacharya M, Bozeman L. , et al; Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360 (9332): 528-534
    CrossrefPubMedGoogle Scholar
  • 9 Chang KC, Leung CC, Grosset J, Yew WW. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011; 66 (11) 997-1007
    CrossrefPubMedGoogle Scholar
  • 10 Alipanah N, Cattamanchi A, Menzies R, Hopewell PC, Chaisson RE, Nahid P. Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis. Int J Tuberc Lung Dis 2016; 20 (11) 1522-1528
    CrossrefPubMedGoogle Scholar
  • 11 Jindani A, Harrison TS, Nunn AJ. , et al; RIFAQUIN Trial Team. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371 (17) 1599-1608
    CrossrefPubMedGoogle Scholar
  • 12 Merle CS, Fielding K, Sow OB. , et al; OFLOTUB/Gatifloxacin for Tuberculosis Project. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371 (17) 1588-1598
    CrossrefPubMedGoogle Scholar
  • 13 Gillespie SH, Crook AM, McHugh TD. , et al; REMoxTB Consortium. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371 (17) 1577-1587
    CrossrefPubMedGoogle Scholar
  • 14 Murray S, Mendel C, Spigelman M. TB Alliance regimen development for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016; 20 (12) 38-41
    CrossrefPubMedGoogle Scholar
  • 15 Dawson R, Diacon AH, Everitt D. , et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015; 385 (9979): 1738-1747
    CrossrefPubMedGoogle Scholar
  • 16 Johnston JC, Campbell JR, Menzies D. Effect of intermittency on treatment outcomes in pulmonary tuberculosis: an updated systematic review and metaanalysis. Clin Infect Dis 2017; 64 (09) 1211-1220
    CrossrefPubMedGoogle Scholar
  • 17 Ngwatu BK, Nsengiyumva NP, Oxlade O. , et al; Collaborative Group on the Impact of Digital Technologies on TB. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J 2018; 51 (01) 51
    CrossrefPubMedGoogle Scholar
  • 18 Guidelines on the Management of Latent Tuberculosis Infection. Geneva, Switzerland: World Health Organization; 2015
    Google Scholar
  • 19 Latent TB. Infection: Updated and consolidated guidelines for programmatic management. Geneva, Switzerland: World Health Organization; 2018
    Google Scholar
  • 20 Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1 (7760): 1079-1085
    PubMedGoogle Scholar
  • 21 Long MW, Snider Jr DE, Farer LS. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119 (06) 879-894
    PubMedGoogle Scholar
  • 22 van Ingen J, Aarnoutse RE, Donald PR. , et al. Why do we use 600 mg of rifampicin in tuberculosis treatment?. Clin Infect Dis 2011; 52 (09) e194-e199
    CrossrefPubMedGoogle Scholar
  • 23 Jayaram R, Gaonkar S, Kaur P. , et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47 (07) 2118-2124
    CrossrefPubMedGoogle Scholar
  • 24 Rosenthal IM, Tasneen R, Peloquin CA. , et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012; 56 (08) 4331-4340
    CrossrefPubMedGoogle Scholar
  • 25 de Steenwinkel JE, Aarnoutse RE, de Knegt GJ. , et al. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med 2013; 187 (10) 1127-1134
    CrossrefPubMedGoogle Scholar
  • 26 Steingart KR, Ng V, Henry M. , et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6 (10) 664-674
    CrossrefPubMedGoogle Scholar
  • 27 Ruslami R, Ganiem AR, Dian S. , et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13 (01) 27-35
    CrossrefPubMedGoogle Scholar
  • 28 Boeree MJ, Diacon AH, Dawson R. , et al; PanACEA Consortium. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015; 191 (09) 1058-1065
    CrossrefPubMedGoogle Scholar
  • 29 Aarnoutse RE, Kibiki GS, Reither K. , et al; PanACEA Consortium. Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2017; 61 (11) 61
    PubMedGoogle Scholar
  • 30 Boeree MJ, Heinrich N, Aarnoutse R. , et al; PanACEA consortium. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis 2017; 17 (01) 39-49
    CrossrefPubMedGoogle Scholar
  • 31 Heifets LB, Lindholm-Levy PJ, Flory MA. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis . Am Rev Respir Dis 1990; 141 (03) 626-630
    CrossrefPubMedGoogle Scholar
  • 32 Mor N, Simon B, Mezo N, Heifets L. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother 1995; 39 (09) 2073-2077
    CrossrefPubMedGoogle Scholar
  • 33 Sirgel FA, Fourie PB, Donald PR. , et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005; 172 (01) 128-135
    CrossrefPubMedGoogle Scholar
  • 34 Dhillon J, Mitchison DA. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis 1992; 145 (01) 212-214
    CrossrefPubMedGoogle Scholar
  • 35 Dorman SE, Goldberg S, Stout JE. , et al; Tuberculosis Trials Consortium. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis 2012; 206 (07) 1030-1040
    CrossrefPubMedGoogle Scholar
  • 36 Savic RM, Weiner M, MacKenzie WR. , et al; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther 2017; 102 (02) 321-331
    CrossrefPubMedGoogle Scholar
  • 37 Jayakumar A, Savic RM, Everett CK. , et al. Xpert MTB/RIF assay shows faster clearance of Mycobacterium tuberculosis DNA with higher levels of rifapentine exposure. J Clin Microbiol 2016; 54 (12) 3028-3033
    CrossrefPubMedGoogle Scholar
  • 38 Dorman SE, Savic RM, Goldberg S. , et al; Tuberculosis Trials Consortium. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med 2015; 191 (03) 333-343
    CrossrefPubMedGoogle Scholar
  • 39 Lounis N, Bentoucha A, Truffot-Pernot C. , et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001; 45 (12) 3482-3486
    CrossrefPubMedGoogle Scholar
  • 40 Rosenthal IM, Williams K, Tyagi S. , et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 2006; 174 (01) 94-101
    CrossrefPubMedGoogle Scholar
  • 41 Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis 2017; 17 (02) 223-234
    CrossrefPubMedGoogle Scholar
  • 42 Schechter MC, Bizune D, Kagei M. , et al. Time to sputum culture conversion and treatment outcomes among patients with isoniazid-resistant tuberculosis in Atlanta, Georgia. Clin Infect Dis 2017; 65 (11) 1862-1871
    CrossrefPubMedGoogle Scholar
  • 43 Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990; 112 (06) 407-415
    CrossrefPubMedGoogle Scholar
  • 44 Burman W, Benator D, Vernon A. , et al; Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173 (03) 350-356
    CrossrefPubMedGoogle Scholar
  • 45 Gopalan N, Santhanakrishnan RK, Palaniappan AN. , et al. Daily vs intermittent antituberculosis therapy for pulmonary tuberculosis in patients with HIV: a randomized clinical trial. JAMA Intern Med 2018; 178 (04) 485-493
    CrossrefPubMedGoogle Scholar
  • 46 Nahid P, Dorman SE, Alipanah N. , et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63 (07) e147-e195
    CrossrefPubMedGoogle Scholar
  • 47 WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva, Switzerland: World Health Organization; 2017
    Google Scholar
  • 48 Kamolratanakul P, Sawert H, Lertmaharit S. , et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999; 93 (05) 552-557
    CrossrefPubMedGoogle Scholar
  • 49 Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 2001; 357 (9257): 664-669
    CrossrefPubMedGoogle Scholar
  • 50 Weis SE, Slocum PC, Blais FX. , et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330 (17) 1179-1184
    CrossrefPubMedGoogle Scholar
  • 51 Pasipanodya JG, Gumbo T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin Infect Dis 2013; 57 (01) 21-31
    CrossrefPubMedGoogle Scholar
  • 52 Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2015; (05) CD003343
    PubMedGoogle Scholar
  • 53 McLaren ZM, Milliken AA, Meyer AJ, Sharp AR. Does directly observed therapy improve tuberculosis treatment? More evidence is needed to guide tuberculosis policy. BMC Infect Dis 2016; 16 (01) 537
    CrossrefPubMedGoogle Scholar
  • 54 Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 1997; 112 (01) 63-70
    CrossrefPubMedGoogle Scholar
  • 55 Weis SE, Foresman B, Matty KJ. , et al. Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis: a comparative analysis. Int J Tuberc Lung Dis 1999; 3 (11) 976-984
    PubMedGoogle Scholar
  • 56 Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. Int J Tuberc Lung Dis 2016; 20 (05) 588-593
    CrossrefPubMedGoogle Scholar
  • 57 DeMaio J, Schwartz L, Cooley P, Tice A. The application of telemedicine technology to a directly observed therapy program for tuberculosis: a pilot project. Clin Infect Dis 2001; 33 (12) 2082-2084
    CrossrefPubMedGoogle Scholar
  • 58 Steffen R, Menzies D, Oxlade O. , et al. Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLoS One 2010; 5 (11) e14014
    CrossrefPubMedGoogle Scholar
  • 59 Krueger K, Ruby D, Cooley P. , et al. Videophone utilization as an alternative to directly observed therapy for tuberculosis. Int J Tuberc Lung Dis 2010; 14 (06) 779-781
    PubMedGoogle Scholar
  • 60 Garfein RS, Collins K, Muñoz F. , et al. Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study. Int J Tuberc Lung Dis 2015; 19 (09) 1057-1064
    CrossrefPubMedGoogle Scholar
  • 61 A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1989; 139 (04) 871-876
    CrossrefPubMedGoogle Scholar
  • 62 Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Fourteenth report of the Medical Research Council Working Party on Tuberculosis of the Spine. Int Orthop 1999; 23 (02) 73-81
    CrossrefPubMedGoogle Scholar
  • 63 el-Sadr WM, Perlman DC, Matts JP. , et al; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998; 26 (05) 1148-1158
    CrossrefPubMedGoogle Scholar
  • 64 Chideya S, Winston CA, Peloquin CA. , et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48 (12) 1685-1694
    CrossrefPubMedGoogle Scholar
  • 65 Swaminathan S, Pasipanodya JG, Ramachandran G. , et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis 2016; 63 (Suppl. 03) S63-S74
    CrossrefPubMedGoogle Scholar
  • 66 Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208 (09) 1464-1473
    CrossrefPubMedGoogle Scholar
  • 67 Haas MK, Daley CL. Mycobacterial lung disease complicating HIV infection. Semin Respir Crit Care Med 2016; 37 (02) 230-242
    Article in Thieme ConnectPubMedGoogle Scholar
  • 68 Vernon A, Burman W, Benator D, Khan A, Bozeman L. ; Tuberculosis Trials Consortium. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353 (9167): 1843-1847
    CrossrefPubMedGoogle Scholar
  • 69 Mfinanga SG, Kirenga BJ, Chanda DM. , et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis 2014; 14 (07) 563-571
    CrossrefPubMedGoogle Scholar
  • 70 Nahid P, Dorman SE, Alipanah N. , et al. Executive summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63 (07) 853-867
    CrossrefPubMedGoogle Scholar
  • 71 Nahid P, Gonzalez LC, Rudoy I. , et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175 (11) 1199-1206
    CrossrefPubMedGoogle Scholar
  • 72 Blanc FX, Sok T, Laureillard D. , et al; CAMELIA (ANRS 1295–CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365 (16) 1471-1481
    CrossrefPubMedGoogle Scholar
  • 73 Abdool Karim SS, Naidoo K, Grobler A. , et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362 (08) 697-706
    CrossrefPubMedGoogle Scholar
  • 74 Abdool Karim SS, Naidoo K, Grobler A. , et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365 (16) 1492-1501
    CrossrefPubMedGoogle Scholar
  • 75 Havlir DV, Kendall MA, Ive P. , et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365 (16) 1482-1491
    CrossrefPubMedGoogle Scholar
  • 76 Török ME, Yen NT, Chau TT. , et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)–associated tuberculous meningitis. Clin Infect Dis 2011; 52 (11) 1374-1383
    CrossrefPubMedGoogle Scholar
  • 77 Meintjes G, Lawn SD, Scano F. , et al; International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8 (08) 516-523
    CrossrefPubMedGoogle Scholar
  • 78 Naidoo K, Yende-Zuma N, Padayatchi N. , et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157 (05) 313-324
    CrossrefPubMedGoogle Scholar
  • 79 Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21 (03) 335-341
    CrossrefPubMedGoogle Scholar
  • 80 Meintjes G, Wilkinson RJ, Morroni C. , et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24 (15) 2381-2390
    PubMedGoogle Scholar
  • 81 Baghaei P, Marjani M, Tabarsi P. , et al. Impact of chronic renal failure on anti-tuberculosis treatment outcomes. Int J Tuberc Lung Dis 2014; 18 (03) 352-356
    CrossrefPubMedGoogle Scholar
  • 82 Sobhy S, Babiker Z, Zamora J, Khan KS, Kunst H. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. BJOG 2017; 124 (05) 727-733
    CrossrefPubMedGoogle Scholar
  • 83 Bekker A, Schaaf HS, Draper HR, Kriel M, Hesseling AC. Tuberculosis disease during pregnancy and treatment outcomes in HIV-infected and uninfected women at a referral hospital in Cape Town. PLoS One 2016; 11 (11) e0164249
    CrossrefPubMedGoogle Scholar
  • 84 Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010; 161 (01) 1-9
    PubMedGoogle Scholar
  • 85 Keane J, Gershon S, Wise RP. , et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15) 1098-1104
    CrossrefPubMedGoogle Scholar
  • 86 Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 2005; 9 (09) 1057-1058
    PubMedGoogle Scholar
  • 87 Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007; 45 (11) 1470-1475
    CrossrefPubMedGoogle Scholar
  • 88 Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009; 48 (10) 1429-1432
    CrossrefPubMedGoogle Scholar
  • 89 Hsu DC, Faldetta KF, Pei L. , et al. A paradoxical treatment for a paradoxical condition: infliximab use in three cases of mycobacterial IRIS. Clin Infect Dis 2016; 62 (02) 258-261
    CrossrefPubMedGoogle Scholar
  • 90 Kim YJ, Kim YG, Shim TS. , et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford) 2014; 53 (08) 1477-1481
    CrossrefPubMedGoogle Scholar
  • 91 Kim HW, Kwon SR, Jung KH. , et al; Korean Society of Spondyloarthritis Research. Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: a retrospective nationwide registry of the Korean Society of Spondyloarthritis Research. PLoS One 2016; 11 (04) e0153816
    CrossrefPubMedGoogle Scholar
  • 92 Ozguler Y, Hatemi G, Ugurlu S. , et al. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. Rheumatol Int 2016; 36 (12) 1719-1725
    CrossrefPubMedGoogle Scholar
  • 93 Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2016; 4: CD002244
    CrossrefPubMedGoogle Scholar
  • 94 Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13 (03) 223-237
    CrossrefPubMedGoogle Scholar
  • 95 Mayosi BM, Ntsekhe M, Bosch J. , et al; IMPI Trial Investigators. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014; 371 (12) 1121-1130
    CrossrefPubMedGoogle Scholar
  • 96 Mount FW, Ferebee SH. The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis 1962; 85: 821-827
    PubMedGoogle Scholar
  • 97 Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962; 85: 490-510
    PubMedGoogle Scholar
  • 98 Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis 1963; 88: 161-175
    PubMedGoogle Scholar
  • 99 Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95 (06) 935-943
    PubMedGoogle Scholar
  • 100 International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60 (04) 555-564
    PubMedGoogle Scholar
  • 101 Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130 (06) 1712-1717
    CrossrefPubMedGoogle Scholar
  • 102 Menzies D, Long R, Trajman A. , et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149 (10) 689-697
    CrossrefPubMedGoogle Scholar
  • 103 Halsey NA, Coberly JS, Desormeaux J. , et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351 (9105): 786-792
    CrossrefPubMedGoogle Scholar
  • 104 Gordin F, Chaisson RE, Matts JP. , et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000; 283 (11) 1445-1450
    CrossrefPubMedGoogle Scholar
  • 105 Centers for Disease Control and Prevention (CDC). Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50 (15) 289-291
    PubMedGoogle Scholar
  • 106 Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection–United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52 (31) 735-739
    PubMedGoogle Scholar
  • 107 A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992; 145 (01) 36-41
    CrossrefPubMedGoogle Scholar
  • 108 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; (01) CD000171
    PubMedGoogle Scholar
  • 109 Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness; 2018
    PubMed
  • 110 Sterling TR, Villarino ME, Borisov AS. , et al; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365 (23) 2155-2166
    CrossrefPubMedGoogle Scholar
  • 111 Sandul AL, Nwana N, Holcombe JM. , et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine (3HP) for latent Mycobacterium tuberculosis infection. Clin Infect Dis 2017; 65 (07) 1085-1093
    CrossrefPubMedGoogle Scholar
  • 112 Belknap R, Holland D, Feng PJ. , et al; TB Trials Consortium iAdhere Study Team. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med 2017; 167 (10) 689-697
    CrossrefPubMedGoogle Scholar
  • 113 Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med 2017; 167 (04) 248-255
    CrossrefPubMedGoogle Scholar
  • 114 Swindells SR, Ramchandani R, Gupta A. One month of rifapentine/isoniazid to prevent TB in people with HIV: brief-TB/A5279. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA; March 4–7, 2018
    PubMedGoogle Scholar
  • 115 2017 Pipeline Report. 2017. Available at: http://www.treatmentactiongroup.org/pipeline-report/2017 . Accessed March 19, 2018
    PubMed
  • 116 Bamrah S, Brostrom R, Dorina F. , et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis 2014; 18 (08) 912-918
    CrossrefPubMedGoogle Scholar
  • 117 Nelson Mandela, a special champion of TB and HIV/AIDS, dies in Johannesburg. Union Against Tuberculosis and Lung Disease, 2013. Available at: https://www.theunion.org/news-centre/news/nelson-mandela-a-special-champion-of-tb-and-hivaids-dies-in-johannesburg . Accessed May 20, 2018
    PubMed